CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.11BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.01xvs all stocks
52-Week Change
-2.98%vs all stocks
Market Capitalization
1.11BUSDvs all stocks (USD)
Enterprise Value
835.54MUSDvs all stocks (USD)
Forward P/E
-6.69xvs Biotechnology peers
Price to Book (MRQ)
2.67xvs Biotechnology peers
Enterprise to EBITDA
-5.62xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-27.57%vs Biotechnology peers
Return on Equity (TTM)
-42.57%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-148.72MUSDvs all stocks (USD)
Net Income (TTM)
-135.21MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-110.88MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-67.97MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-143.00MUSDvs all stocks (USD)
Pre-tax Income
-129.47MUSDFY2025 · Dec 31, 2025Net Income
-129.47MUSDFY2025 · Dec 31, 2025EBIT
-143.00MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-141.78MUSDFY2025 · Dec 31, 2025Research & Development
109.82MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
33.19MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-129.47MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-103.21MUSDFY2025 · Dec 31, 2025Free Cash Flow
-103.92MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
46.16MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-129.47MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.22MUSDFY2025 · Dec 31, 2025Stock-based Compensation
25.04MUSDFY2025 · Dec 31, 2025Capital Expenditures
-712.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-399.82MUSDFY2025 · Dec 31, 2025Sale of Investments
252.50MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-148.03MUSDFY2025 · Dec 31, 2025Other Financing Charges
-2.40MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
241.97MUSDFY2025 · Dec 31, 2025Shares Outstanding
103.49MSharesUpdated Jul 19, 2026Float Shares
82.72MSharesUpdated Jul 19, 2026Shares Short
22.11MSharesUpdated Jul 19, 2026Short Ratio
11.29daysvs all stocks
Short % of Shares Outstanding
21.58%vs all stocks
% Held by Insiders
5.85%vs all stocks
% Held by Institutions
113.93%vs all stocks
Total Cash (MRQ)
281.93MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.72USDUpdated Jul 19, 2026Total Debt (MRQ)
6.73MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0162xvs Biotechnology peers
Current Ratio (MRQ)
16.33xvs Biotechnology peers
Book Value per Share (MRQ)
4.02USDUpdated Jul 19, 2026Total Assets
408.89MUSDvs all stocks (USD)
Total Current Assets
288.47MUSDFY2025 · Dec 31, 2025Total Liabilities
24.53MUSDFY2025 · Dec 31, 2025Total Non-current Assets
120.42MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
4.11MUSDFY2025 · Dec 31, 2025Total Current Liabilities
20.42MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
45.67MUSDFY2025 · Dec 31, 2025Other Short-term Investments
235.82MUSDFY2025 · Dec 31, 2025Accounts Payable
3.82MUSDFY2025 · Dec 31, 2025Short-term Debt
3.33MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
4.11MUSDFY2025 · Dec 31, 2025Common Stock (Book)
11.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-692.24MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
384.36MUSDvs all stocks (USD)
52-Week Low
7.23USDUpdated Jul 19, 202652-Week High
14.93USDUpdated Jul 19, 202652-Week Change
-2.98%vs all stocks
Beta
1.01xvs all stocks
50-Day MA
9.12USDUpdated Jul 19, 2026200-Day MA
10.67USDUpdated Jul 19, 2026Avg 10-Day Volume
1.58MSharesUpdated Jul 19, 2026Avg 30-Day Volume
1.69MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.39USDUpdated Jul 19, 2026Other Income / Expense
13.54MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.76
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Shinva Medical Instrument Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sichuan Huiyu Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inventiva S.A.
Tier 1ProductionApproval-Gated PipelineRule
Inkon Life Tech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
EyePoint Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
China Resources Boya Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangxi Wuzhou Zhongheng Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Frontier Biotechnologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Star Lake Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Wave Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk